New cancer drug KK2269 enters first human tests

NCT ID NCT06266299

Recruiting now Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 alone, then testing it with docetaxel in specific cancer types.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KK2269 (an experimental drug) and docetaxel (a chemotherapy drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial focused on safety, not effectiveness. The drug may not work or could cause serious side effects. It will take years before any potential treatment is available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Aichi Cancer Center
RECRUITING

Nagoya, Aichi-ken, 464-8681, Japan
Cancer Institute Hospital of JFCR
RECRUITING

Koto-Ku, Tokyo, 135-8550, Japan
City Of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92663, United States
Mayo Clinic Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States
Mayo Clinic Jacksonville
RECRUITING

Jacksonville, Florida, 32224, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
The University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Washington
RECRUITING

Seattle, Washington, 98195, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.